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HeparinJike inhibitor of
blood coagulation in normal newborn
Tnr level of the blood coagulation factors in the newborn
is known to be markedly lower than that in the adult.
Generally this is attributed to a lack of synthetic capacity
of the liver and a deficiency in vitamin K. We describe here
a re-investigation of this problem making use of recently
developed methods that determine both the coagulation
factors and the abnormal proteins induced by vitamin K
absence (PIVKAs). We found low coagulation factor activity
in the newborn but no evidence for vitamin K deflciency.
In more than half the samples a hitherto unrecognised
inhibitor of blood coagulation could be demonstrated. At
3 d of age this inhibitor was found in all babies investigated.
On the basis of its properties in blood coagulation tests the
inhibitor could not be distinguished from heparin.
In 43 healthy newborns a 20-cm piece of umbilical cord
was clamped directly after birth and 9-ml of blood was
withdrawn by puncture from the vena umbilicalis into a
polypropylene syringe containing 1 ml of a solution contain-
ing HEPES 0.3 M, trisodium citrate 0.1 M, sodium azide
15 mM, Trasylol (Bayer) 50 U, pH 7.3. This mixture effec-
tively prevents fibrinolysis. Plasma was obtained by centrifu-
gation and spun platelet poor by a second centrifugation
(30 min 4'C, 20,0009). It was frozen in l-ml aliquots and
stored at -20'C until further use. In these plasmas we
determined clotting factors V, VII, and X and prothrombin
by a one-stage procedure and prothrombin also by a two-
stage procedure (Table 1). Experimental methods were as
described in ref. l.
In 27 of the 43 plasmas the disappearance rate of
thrombin in the two-stage prothrombin assay was
significantly (>5 times) greater than in normal human adult
plasma. In the 16 others it was no more than 1.8 times
greater than normal. On the basis of this observation we
divided the plasma in an inactivated and a non-inactivated
group. We found no significant differences in antithrombin
III, ar-antitrypsin, a2-m4sloglobulin, antiplasmin, C1-esterase
inhibitor and inter-a-trypsin inhibitor activities between in-
activated and non-inactivated plasma samples: we therefore
conclude that none of these proteins are responsible for the
inactivation. No fibrinogen degradation products could be
detected in either of the plasmas. Pooled inactivated and
pooled non-inactivated plasma was diluted 20-fold with
Table I Determination of clottine factors in cord blood
616*617,  June 16 ,1977)
I  9 7 7
Values are means * s.d. of the blood activities as % of pooled blood
from 30 normal adults. I, group showing rapid thrombin inactivation(n:27): Non-I, group showing normal thrombin inactivation(n : l6). CIE, crossed immunoelectrophoresis,
distilled water; isoelectric precipitation at pH 5,2 yielded a
fraction containing prothrombin but no thrombin inhibitors.
In such fractions made from both plasma types, thrombin
generated normally and was not inactivated. In the presence
of normal plasma the thrombin thus generated inactivated
normally. This excluded the possibility that the rapid
inactivation was due to an abnormality of the (pro)thrombin
molecule in the inactivated plasma.
Both procoagulants and thrombin inactivating proteins
in inactivated plasma were precipitated by phosphotungstic
acid (1 13 volume ot 1O% phosphotungstic acid in 0.67N
H:SOr). After neutralisation and removal of the phospho-
tungst,ic acid, the resulting fraction accelerated thrombin
inactivation in normal plasma by a factor five to seven, and
lost its inactivation enhancing properties on addition of
12 p.gml-' protamine sulphate. No such fraction could be
obtained from the non-inactivated plasma. Inactivation of
thrombin in inactivated plasma could be prevented by
addition of 14 ttg m1-' of protamine sulphate whereas such
addition had little or no effect on non-inactivated plasma.
Heparin is known to potentiate thrombin inactivation by
antithrombin III, to be neutralised by protamine sulphate
and not to be precipitated by phosphotungstic acid'.
We conclude that the inactivated plasma contains heparin
or a substance with heparin-like properties. The source of
this substance is presumably in the newborn. It could not be
demonstrated in maternal blood or in the perfused placenta.
Five children who did not show enhanced inactivation in
the cord blood did show this activity in blood taken from the
vena cubiti on day 3 of life. The 1l others from the non-
inactivated group were not tested.
Presumably this heparinlike substance is produced in
organs that are hardly perfused before birth, but will have
an active circulation afterwards (that is, the lungs). It rnay
serve to prevent thrombosis in these organs. In this context
it is interesting to note that complete deficiency of anti-
thrombin has never been observed although several series of
(possibly heterozygous) patients with about a half normal
amount of antithrombin III have been reported3. Complete
absence of antithrombin III which would prevent the action
of the heparinJike substance might be a lethal condition.
We found no differences between the inactivated and
non-inactivated groups in any of the coagulation factors
Fig. I Thrombin generation and breakdown in pooled new-
born plasmas with (O) and without (f ) inactivating substance.
Reaction mixture: 0.2 ml plasma, 0.1 n-rl hun-ran brain thrombo-
plastin, 1.7 ml Michaelis bufferpH 7.2, 1n' l  CaClr 33 mM. At
the times indicated 0.1 ml of the reaction mixture was sub-
sampled into 0.1 ml of BaSOo adsorbed plasma diluted l:5 with
Michaelis buffer (pH 7.2). From the clotting time obtained the
thrombin content was calculatedl.
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tested. More interesting, there was no discrepancy between
the prothrombin contents found with the one-stage and the
two-stage assay (Table l). This indicates that no proteins
induced by vitamin K absence (PIVKAs) are present in the
plasma of the newbornn. This is corroborated by the fact
that neither in the staphylocoagulase test nor in the Echis
Carinatus test nor in a one-dimensional immuno electro-
phoresis an excess of prothrornbin activity was observed
whereas the PIVKA when present would co-estimate in
these tests (Table l, ref. 1).
We concluded that, contrary to current beliefs, the new-
born has no vitamin K deficiency but is 'anticoagulated' by
heparin or a heparinlike substance.
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